What We Are Doing...

Autosomal Dominant Alzheimer’s Disease (ADAD) is a rare form of Alzheimer’s that causes memory loss and dementia in people in their 30s to 50s.

The Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU) at Washington University has launched the first prevention trial for ADAD families. The DIAN-TU trial focuses on drugs that could potentially change the course of the disease. The trial’s goal is to determine the safety, tolerability, and effectiveness of these drugs. The DIAN-TU trial will determine if these medications can prevent, delay, or possibly even reverse Alzheimer’s disease changes in the brain.

Although there are differences between ADAD and the more common age-associated, sporadic Alzheimer’s disease, the results of this study will have implications for future studies and treatments in sporadic Alzheimer’s disease.

How You Can Help

Are you or someone you know affected by ADAD? We are currently looking for participants that have a parent or sibling who has been affected by an ADAD mutation.

If you or someone you know fits this description, contact us toll-free at:

1-844-342-6397 or www.DIANexr.org
to find out more!
Are You Eligible To Participate?

⇒ Does your family have an ADAD mutation (PSEN1, PSEN2, or APP) for early onset Alzheimer’s disease (less than 60 years) in multiple generations?
⇒ Are you cognitively normal, or do you have mild dementia? Both are eligible for this prevention trial.
⇒ Are you between the ages 18 to 80?
⇒ Are you between 15 years younger to 10 years older than your parent was when they first showed the signs of Alzheimer’s disease?
⇒ Do you have a family member or friend that can accompany you to visits and provide information about your medical history?

If you answered YES to ALL the above questions, you may be eligible to participate.

Please call us at 1-844-DIAN-EXR (342-6397) or email dianexr@wustl.edu

I Still Have Some Questions...

⇒ Can participants taking medications for memory impairment remain on their medications during the trial? Yes. Participants may remain on prescription medications. However, the medication dose must be stable before entering the study.
⇒ Can I participate in this trial if I do not want to find out my mutation status? Yes! You CAN participate in this trial even if you don’t want to know your mutation status. The mutation in the family needs to be known for the trial, but individuals do not need to know their mutation status.
⇒ Does this trial have a placebo group? Yes. In order to determine the effectiveness or action of the study drugs, the trial includes a placebo; there is a ratio of 3:1 (drug: placebo), so participants have a 75% chance of receiving active drug.
⇒ Who decides whether participants get the active drug or placebo? A computer system randomly assigns participants to active drug or placebo.
⇒ How long would a person be in a trial? The first part of the trial is planned for 24 months, and may be extended if successful.
⇒ What if I can’t get off work for study visits? There are trained home health nurses that can come to your home or other location, including after hours and weekends.
⇒ Where can I find more information about the DIAN-TU trial and study sites? If you would like more information, please contact the DIAN Expanded Registry at www.DIANexr.org or call 1-844-DIAN-EXR (342-6397)

What Happens Next?

If you are interested in participating in the trial and meet the eligibility criteria, a study coordinator will contact you to discuss the study schedule, send you a form with all the study details, and if you wish to, enroll you in the trial. Below is a brief view of the study schedule:

- Initial Screening (3-4 hours)
- Monthly Visit: Administration of drug
- Every 3 months: MRI safety scan
- Every 6 months: Cognitive testing on an iPad
- Annual Visit: 3-4 day visit including physical examination, blood sampling, imaging [PET & MRI], cognitive testing, lumbar puncture, and drug dosing. There are 3 of these annual visits.

If you are interested in participating, call: 1-844-DIAN-EXR (342-6397) or email: dianexr@wustl.edu